CN100506791C - 五氟硫基苯甲酰基胍、其制备方法、其作为药物或诊断剂的用途以及包含它们的药物 - Google Patents

五氟硫基苯甲酰基胍、其制备方法、其作为药物或诊断剂的用途以及包含它们的药物 Download PDF

Info

Publication number
CN100506791C
CN100506791C CNB038113198A CN03811319A CN100506791C CN 100506791 C CN100506791 C CN 100506791C CN B038113198 A CNB038113198 A CN B038113198A CN 03811319 A CN03811319 A CN 03811319A CN 100506791 C CN100506791 C CN 100506791C
Authority
CN
China
Prior art keywords
treatment
formula
pharmaceutically acceptable
nervous system
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038113198A
Other languages
English (en)
Chinese (zh)
Other versions
CN1653044A (zh
Inventor
H-W·克勒曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN1653044A publication Critical patent/CN1653044A/zh
Application granted granted Critical
Publication of CN100506791C publication Critical patent/CN100506791C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB038113198A 2002-05-18 2003-05-05 五氟硫基苯甲酰基胍、其制备方法、其作为药物或诊断剂的用途以及包含它们的药物 Expired - Fee Related CN100506791C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10222192A DE10222192A1 (de) 2002-05-18 2002-05-18 Pentafluorsulfuranyl-benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10222192.8 2002-05-18

Publications (2)

Publication Number Publication Date
CN1653044A CN1653044A (zh) 2005-08-10
CN100506791C true CN100506791C (zh) 2009-07-01

Family

ID=29285565

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038113198A Expired - Fee Related CN100506791C (zh) 2002-05-18 2003-05-05 五氟硫基苯甲酰基胍、其制备方法、其作为药物或诊断剂的用途以及包含它们的药物

Country Status (28)

Country Link
EP (1) EP1509498B1 (enExample)
JP (1) JP4383341B2 (enExample)
KR (1) KR100977676B1 (enExample)
CN (1) CN100506791C (enExample)
AR (1) AR040034A1 (enExample)
AT (1) ATE343563T1 (enExample)
AU (1) AU2003242531B2 (enExample)
BR (1) BR0311128A (enExample)
CA (1) CA2486336C (enExample)
CY (1) CY1105867T1 (enExample)
DE (2) DE10222192A1 (enExample)
DK (1) DK1509498T3 (enExample)
ES (1) ES2274264T3 (enExample)
HR (1) HRP20041078B1 (enExample)
IL (2) IL165213A0 (enExample)
MA (1) MA27277A1 (enExample)
ME (1) MEP28908A (enExample)
MX (1) MXPA04011497A (enExample)
MY (1) MY139310A (enExample)
NO (1) NO333288B1 (enExample)
PE (1) PE20040452A1 (enExample)
PL (1) PL209700B1 (enExample)
PT (1) PT1509498E (enExample)
RS (1) RS50772B (enExample)
RU (1) RU2315752C2 (enExample)
TW (1) TWI281467B (enExample)
WO (1) WO2003097591A1 (enExample)
ZA (1) ZA200408886B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501440B2 (en) 2003-03-07 2009-03-10 Sanofi-Aventis Deutschland Gmbh Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
DE10338554A1 (de) * 2003-08-22 2005-03-31 Aventis Pharma Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
OA13285A (en) * 2003-11-13 2007-01-31 Sanofi Aventis Deutschland Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same.
DE10353204A1 (de) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von 4-Pentafluorsulfanyl-benzoylguanidinen
DE10353205A1 (de) * 2003-11-13 2005-06-16 Aventis Pharma Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als wertvolle Synthese-Zwischenstufen
DE102004043937A1 (de) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Ortho-substituierte Pentafluorsulfuranyl-Benzole, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Synthese-Zwischenstufen
DE102004043938A1 (de) * 2004-09-11 2006-03-30 Sanofi-Aventis Deutschland Gmbh Pentafluorosulfanylphenyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
WO2008096231A1 (en) * 2007-02-09 2008-08-14 Pfizer Limited Antiparasitic agents
WO2008118787A1 (en) * 2007-03-23 2008-10-02 Im & T Research, Inc. Process for producing arylsulfur pentafluorides
JP5418226B2 (ja) * 2007-08-28 2014-02-19 宇部興産株式会社 ペンタフルオロスルファニルベンゼン化合物の製造方法、及び新規なペンタフルオロスルファニルベンゼン化合物
RU2372331C1 (ru) * 2008-05-14 2009-11-10 Сергей Михайлович Игумнов СПОСОБ ПОЛУЧЕНИЯ ДИ(C1-C6 алкил)АМИНОТРИФТОРСУЛЬФУРАНОВ
JP5439745B2 (ja) * 2008-05-27 2014-03-12 宇部興産株式会社 ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法
JP6124015B2 (ja) * 2011-12-06 2017-05-10 宇部興産株式会社 ペンタフルオロスルファニル安息香酸の製造方法
CN108003034B (zh) * 2017-12-26 2020-07-03 金凯(辽宁)化工有限公司 一种2-甲基-5-氨基三氟甲苯的制备方法
RU2765117C2 (ru) * 2019-09-24 2022-01-25 Федеральное государственное автономное образовательное учреждение высшего образования "Уральский федеральный университет имени первого Президента России Б.Н. Ельцина" Применение натриевой соли диэтилового эфира 4-оксо-1,4-дигидропиразоло[5,1-с]-1,2,4-триазин-3,8-дикарбоновой кислоты, моногидрата в качестве средства лечения и профилактики поздних осложнений сахарного диабета

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4417004A1 (de) * 1994-05-13 1995-11-16 Hoechst Ag Perfluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19517848A1 (de) * 1995-05-16 1996-11-21 Merck Patent Gmbh Fluorhaltige Benzoylguanidine
DE19526381A1 (de) * 1995-07-19 1997-01-23 Hoechst Ag 4-Fluoralkyl-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
GB9606015D0 (en) * 1996-03-22 1996-05-22 Rhone Poulenc Agriculture New herbicides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARYLSULFUR PENTAFLUORIDES. SHEPPARD W A.JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,Vol.84 No.16. 1962 *

Also Published As

Publication number Publication date
PE20040452A1 (es) 2004-08-18
IL165213A0 (en) 2005-12-18
RS99004A (sr) 2007-04-10
CA2486336C (en) 2011-06-21
EP1509498B1 (de) 2006-10-25
MEP28908A (en) 2010-10-10
DK1509498T3 (da) 2007-02-26
JP4383341B2 (ja) 2009-12-16
MY139310A (en) 2009-09-30
DE50305498D1 (de) 2006-12-07
DE10222192A1 (de) 2003-11-27
RU2004137115A (ru) 2005-05-27
AR040034A1 (es) 2005-03-09
IL165213A (en) 2009-05-04
PL371784A1 (en) 2005-06-27
ES2274264T3 (es) 2007-05-16
HRP20041078B1 (hr) 2013-02-28
TW200407290A (en) 2004-05-16
RU2315752C2 (ru) 2008-01-27
NO333288B1 (no) 2013-04-29
AU2003242531A1 (en) 2003-12-02
ATE343563T1 (de) 2006-11-15
AU2003242531B2 (en) 2008-07-31
EP1509498A1 (de) 2005-03-02
HRP20041078A2 (en) 2005-04-30
CA2486336A1 (en) 2003-11-27
KR100977676B1 (ko) 2010-08-25
ZA200408886B (en) 2006-01-25
NO20045447L (no) 2004-12-14
MXPA04011497A (es) 2005-02-14
CY1105867T1 (el) 2011-02-02
RS50772B (sr) 2010-08-31
MA27277A1 (fr) 2005-04-01
CN1653044A (zh) 2005-08-10
TWI281467B (en) 2007-05-21
PT1509498E (pt) 2007-01-31
BR0311128A (pt) 2005-03-08
JP2005526138A (ja) 2005-09-02
KR20040111635A (ko) 2004-12-31
PL209700B1 (pl) 2011-10-31
WO2003097591A1 (de) 2003-11-27
HK1076095A1 (zh) 2006-01-06

Similar Documents

Publication Publication Date Title
US8008352B2 (en) Pentafluorosulfanylbenzoylguanidines, processes for their preparation, their use as medicaments or diagnostic aids, and medicaments comprising them
AU2003250821B2 (en) Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament
CN100506791C (zh) 五氟硫基苯甲酰基胍、其制备方法、其作为药物或诊断剂的用途以及包含它们的药物
US20050043401A1 (en) Pentafluorosulfanylphenyl-substituted benzoylguanidines, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them
AU2004268762B2 (en) Pentafluorosulfanyl phenyl-substituted benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing said compounds
JP4528304B2 (ja) ペンタフルオロスルファニルベンゾイルグアニジン、その製造方法、医薬又は診断薬としてのその使用及びそれらを含有する医薬
US7446225B2 (en) Pentafluorosulfanylphenyl-substituted benzoylguanidines, method for the production thereof, their use as a medicament or diagnostic agent, and a medicament containing these compounds
US6878748B2 (en) Fluorinated cycloalkyl-derivatized benzoylguanidines, process for their preparation, their uses as medicament, and medicament containing them
HK1076095B (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
NZ536579A (en) Pentafluorosulfanyl-benzoylguanidine, method for the production thereof and its utilization as medicament or diagnostic agent and medicament containing same
HK1095584B (en) Pentafluorosulfanyl benzoylguanidines, method for their production, their use as medicaments or diagnostic agents and medicament containing the same
NZ537168A (en) Fluorinated cycloalkyl-derivatised benzoylguanidines to protect against the cytotoxic effects of medicaments such as those used in cancer therapy and the therapy of autoimmune diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076095

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1076095

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090701

Termination date: 20150505

EXPY Termination of patent right or utility model